Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two drugs, succinylcholine and neostigmine, used in the context of anesthesia and neuromuscular blockade management. Succinylcholine is a depolarizing neuromuscular blocker that acts as an agonist at nicotinic acetylcholine receptors on the motor endplate, causing persistent depolarization and subsequent muscle paralysis. It is primarily used to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation[3]. Neostigmine is a reversible cholinesterase inhibitor that increases acetylcholine levels at the neuromuscular junction by inhibiting acetylcholinesterase, thereby enhancing cholinergic transmission[5][6][8]. Neostigmine can antagonize (reverse) phase II (desensitizing) block caused by prolonged or high-dose succinylcholine administration but may potentiate phase I (depolarizing) block if given too early[1][2]. The combination does not represent a fixed pharmaceutical product but rather describes their sequential or concurrent use in clinical practice for managing complex neuromuscular blockade scenarios.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on succinylcholine + neostigmine.